Lecigimon (Entacapone, Levodopa, Carbidopa Monohydrate)

Levodopa is converted to dopamine in the brain, providing symptomatic relief. Carbidopa blocks peripheral conversion of levodopa, increasing the amount that reaches the central nervous system. Entacapone inhibits the COMT enzyme, reducing peripheral breakdown of levodopa and extending its therapeutic effect.

The specific dose and dosing schedule of Lecigimon are determined by the prescribing clinician based on the individual patient's disease severity, response to therapy, and other medical considerations. Patients should follow the prescriber's instructions and not adjust the dose on their own.

Safety data for Lecigimon in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will evaluate each case individually and discuss alternatives when appropriate.

To request Lecigimon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lecigimon combines three agents in a single tablet, offering a convenient alternative to separate dosing of levodopa/carbidopa with a COMT inhibitor. Compared with using levodopa/carbidopa alone, the addition of entacapone reduces "off" time and may improve motor stability, though side‑effect profiles should be considered.

Lecigimon should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture, excessive heat, and direct sunlight to maintain product stability throughout its shelf life.

Lecigimon is taken orally, usually with food to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water. Patients should follow the timing and dosing instructions provided by their healthcare professional.

Serious risks include severe liver injury, neuroleptic malignant syndrome, marked depression or suicidal thoughts, and rare allergic reactions such as anaphylaxis. Patients should be monitored regularly for these events, and any sudden changes in mood, skin rash, or fever should prompt immediate medical evaluation.

Lecigimon is contraindicated in patients taking non‑selective MAO inhibitors, those with known hypersensitivity to any component of the product, and individuals with severe hepatic impairment. It should also be used with caution in patients with a history of psychiatric disorders or cardiovascular instability.